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Abstract 
Huntington’s disease (HD) is a fatal neurodegenerative disorder resulting from the 
expansion of a trinucleotide repeat within the HD gene. At the cellular level mutant HTT 
(mHTT) aggregates perturb cellular metabolism, intracellular trafficking and 
mitochondrial function, resulting in the increased production of reactive oxygen species 
(ROS) an event closely linked with nerve cell death. Nuclear factor erythroid 2-related 
factor 2 (NRF2) is a redox-sensitive transcription factor responsible for transcribing 
neuroprotective genes under the control of the antioxidant response element (ARE), 
which work to counteract high intracellular ROS levels. I have identified significant 
increases in cell viability, NRF2 nuclear localization, and ARE-luciferase reporter 
activity following treatment with the NRF2 activator dimercaptopropanol (DMP). DMP 
was also found to increase ARE-directed gene expression and maintain a greater 
proportion of functionally active peroxiredoxin 1 (PRX1) protein levels, resulting in 
increased neuronal survival. For this reason DMP may serve an important role in treating 
HD.  
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Chapter 1 
Introduction 
1.1 Preface 
Huntington’s disease (HD) is a fatal autosomal dominant genetic disease affecting about 
1/30000 individuals in the Canadian population (Jenkins et al. 2005). This disorder is 
characterized by progressive neurodegeneration of GABAergic medium spiny neurons in 
motor control centres throughout the brain including the caudate nuclei and substantia 
nigra as well as cognitive centers in the cerebral cortex and hippocampus (Spokes 1980). 
Before the development of movement disorders, HD often initially presents with 
psychiatric conditions such as depression, aggression, dementia, memory loss as well as 
difficulty with judgement and problem solving skills (Duff et al. 2007).  HD-associated 
neurodegeneration results in motor coordination deficits leading to loss of muscle control 
throughout the body (Young et al. 1986). Individuals with HD experience muscle 
weakness and incoordination in facial and pharyngeal muscles, (lips, tongue and 
esophagus) resulting in dysarthria and difficulty in orchestrating the correct sequence of 
muscle movements necessary for speech (apraxia; Hartelius et al. 2010). Additionally HD 
patients suffer from dysphagia, specifically involving a delayed or intermittent swallow 
reflex as well as an inability to coordinate swallowing with speaking or breathing 
(Leopold and Kagel 1985). The leading causes of death in HD patients are aspiration 
pneumonia resulting from dysphagia; and congestive heart failure due to the weakening 
of cardiac muscles (Heemskerk and Roos 2010). The third-leading cause of death in HD 
patients is suicide, which can likely be attributed to HD-associated psychiatric 
disturbances and a bleak prognosis (Heemskerk and Roos 2010). There is no cure for HD 
and the treatments available to those suffering with the disease serve only to manage the 
most troublesome symptoms. Mood stabilizing drugs such as lithium and valproic acid 
are combined with antidepressants such as fluoxetine to manage psychiatric disorders 
associated with HD (Chiu et al. 2011). Antipsychotics such as haloperidol are combined 
with tetrabenazine in order to suppress the writhing and involuntary movements; however 
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these treatment regimens often exacerbate the psychiatric symptoms and are associated 
with unpleasant side-effects (Gimenez-Roldan and Mateo 1989).   
1.2 Molecular Basis of HD 
HD is caused by a CAG trinucleotide repeat expansion in exon 1 of the HD gene, which 
results in a polyglutamine (polyQ) repeat expansion in the encoded Huntingtin (HTT) 
protein (Landles and Bates 2004). The polyQ domain of HTT is highly polymorphic and 
an extended polyQ repeat confers an increased tendency of mHTT to aggregate, leading 
to the formation of neurotoxic intracellular inclusion bodies (Landles and Bates 2004). 
Accordingly, there is a strong negative correlation between repeat length and age at 
onset; and a positive correlation between repeat length and severity of the disease 
(Landles and Bates 2004). A repeat tract of <35Q is considered non-pathogenic and 
individuals carrying 35-40Q exhibit intermediate penetrance of the disease (Landles and 
Bates 2004). Repeat tracts in excess of 40Q invariably result in adult-onset HD while 
repeats in excess of 100Q give rise to childhood onset HD and represent the most 
aggressive manifestation of the disease (Landles and Bates 2004). Interestingly, the 
polyQ motif forms a polar zipper structure which is known to facilitate HTT association 
with transcription factors that also contain a polyQ region (Suagrs and Rubinsztein 2003).  
The wild-type HTT protein is ubiquitously expressed throughout the nervous system and 
is necessary for embryogenesis and brain development in mice (Zeitlin et al. 1995). HTT 
knockout mice (Hdh -/-) exhibit embryonic lethality before gastrulation at day 8.5; 
whereas HTT knockdown mice (<50%) exhibit aberrant neurogenesis and deformities in 
the cerebral cortex, striatum and hippocampus (Zeitlin et al. 1995).  Although the wild-
type function of HTT remains poorly defined, it has been putatively identified as a 
scaffold protein and mediator of endocytic vesicular transport, interacting with clathrin, 
HTT-interacting proteins (Hips) and HTT-associated proteins (Haps; Pal et al. 2006). 
RNAi knockdown of HTT in post-mitotic D. melanogaster neurons results in vesicle and 
mitochondrial trafficking deficits, and overexpression of HTT has been demonstrated to 
be neuroprotective against serum starvation and mitochondrial insults in mouse striatal 
neurons (Bossy-Wetzel et al. 2008). HTT is suspected to be involved in intracellular 
 
 
3 
 
trafficking based on the association of HTT with endosomal compartments, 
Dynein/Dynactin motors, and microtubules; as well as the presence of both nuclear 
export and nuclear localization signals near the HTT C-terminus (Li et al. 1998; Xia et al. 
2008). Phosphorylation and dephosphorylation of HTT appear to regulate anterograde 
and retrograde axonal transport, respectively in mammals (Zala et al. 2008). Interestingly, 
HTT is believed to be neuroprotective through inhibition of caspase 9 activation and 
increased levels of HTT are able to mitigate the effects of the mutant protein (mHTT) in a 
dose-dependent manner, suggesting that HD pathogenesis may be in part due to loss of 
endogenous HTT function (Rigamonti et al. 2001). 
mHTT undergoes a toxic gain-of-function which not only promotes novel protein-protein 
interactions, but also confers a tendency of the protein to self-associate and form 
oligomeric aggregates and ultimately large protein inclusion bodies (Fox et al. 2011). 
This toxic gain-of-function is strictly dependent on mHTT cleavage by caspase 6, and 
covalent cross-linking by transglutaminase 2, generating mHTT N-terminal oligomers 
(Graham et al. 2006; Zainelli et al. 2005). Initially the smaller mHTT oligomers remain 
soluble in the cytoplasm, interfering with axonal transport, neurotransmission, 
mitochondrial activity and transcriptional regulation (Fox et al. 2011). When cytoplasmic 
mHTT levels rise beyond a critical concentration they rapidly coalesce forming a large 
perinuclear protein inclusion body, believed to be partially neuroprotective through 
sequestration of the highly toxic oligomers (Ossato et al. 2005). mHTT is ubiquitinated 
by E3 ligases but there is evidence that it interferes with and/or overwhelms proteasome 
activity, leading to mHTT accumulation in the cytoplasm (Subramaniam et al. 2010). 
mHTT is also sumoylated by the striatal-specific protein RHES, which increases its 
solubility and cytotoxicity, possibly contributing to the selective nature of 
neurodegeneration in HD, with the effects of mHTT being most severe in striatal neurons 
(Subramaniam et al. 2010).  In addition to acting as physical roadblocks, mHTT 
oligomers interfere with axonal trafficking by binding the anterograde motor kinesin and 
retrograde motor dynactin, effectively paralyzing microtubule-associated transportation 
(Zala et al. 2008). Neurons are highly dependent on vesicle and organelle transport for 
proper neurochemical and electrical signalling, and medium spiny neurons may be 
particularly susceptible to mHTT toxicity as a result of their extensive dendritic processes 
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(Trushina et al. 2004). Not only does mHTT affect neuronal physiology, but it also causes 
non-specific transcriptional repression, through its direct binding to RNA polymerase II 
subunits and global gene silencing through its inactivation of histone acetyltransferases 
(Anderson et al. 2008). mHTT additionally undergoes specific interactions with 
transcription factors such as p53, NF-kB, and SP1 (Ravache et al. 2010). Wild-type HTT 
has been demonstrated to upregulate brain-derived neurotrophic factor (Bdnf) mRNA – 
encoding a key growth factor for the survival and synaptic regulation of striatal neurons, 
HTT also stimulates BDNF vesicular transport; while mHTT expression or HTT 
knockdown diminishes this effect (Toro et al. 2006).  
1.3 Mitochondrial Dysfunction in HD  
Oxidative stress is a hallmark feature of HD and several molecular markers of oxidative 
stress have been identified in post mortem analysis of human brains, such as peroxidized 
unsaturated fatty acids, nitrated proteins and hydroxylated nucleic acids (Ischiropoulos 
and Beckman 2003). Reactive oxygen species (ROS) are the primary mediator of 
oxidative stress, and are generated by the unequal transfer of electrons to molecular 
oxygen, particularly during oxidative phosphorylation in the mitochondria (Ischiropoulos 
and Beckman 2003). mHTT oligomers directly interfere with mitochondrial membrane 
potential and function by binding and depolarizing the mitochondrial membrane, which is 
believed to be facilitated by contact between the mitochondria and the mHTT polyQ 
motif (Bossy-Wetzel et al. 2008). Depolarization of the mitochondrial membrane causes 
opening of the permeability transition pore (PTP) and the release of cytochrome C, which 
proceeds to associate with the apoptosome and trigger cell-autonomous apoptotic 
signalling and neuronal cell death (Bossy-Wetzel et al. 2008). mHTT also binds and 
inhibits complex II of the electron transport chain as well as mitochondrial fission and 
fusion regulators such as dynamin related peptide (DRP1) and mitofusin (MF1), which 
results in mitochondrial stress and a net increase in the generation of ROS (Jana et al. 
2001; Olivera 2010). 
The mHTT protein also interferes with mitochondrial function indirectly through 
inhibition of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), 
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which is a transcriptional regulator of genes involved in mitochondrial biogenesis, 
respiration and oxidative stress defense (Bossy-Wetzel et al. 2008; Lin et al. 2004). There 
is evidence that mHTT binds and inactivates the cAMP response element binding protein 
(CREB) transcriptional activator, resulting in reduced expression of PGC-1α and its 
effectors such as nuclear respiration factor-1 (NRF1; Bossy-Wetzel et al. 2008). PGC-1α 
knockout experiments in mice reveal strikingly similar patterns of neurodegeneration to 
HD and studies using transgenic mice expressing mHtt demonstrated a notable reduction 
in PGC-1α protein levels, which was most pronounced in medium spiny neurons as 
compared with interneurons (Lin et al. 2004; Neumann and Cao 2008). This leads to the 
hypothesis that HD-induced loss of PGC-1α may be a contributor to the selective nature 
of striatal-specific neurodegeneration observed in HD (Cui et al. 2006). Medium spiny 
neurons may also be more susceptible to mHTT-induced toxicity than other neuron types 
as a result of their high energetic demands and long projections to other regions of the 
brain rendering them particularly sensitive to mitochondrial function and trafficking 
defects (Bossy-Wetzel et al. 2008).   
1.4 NRF2 and the Antioxidant Response Element 
Although mitochondrial insults can sensitize neurons to apoptosis, there are ROS 
scavenging enzymes that work to counteract oxidative stress by serving as competitive 
oxidative targets (Neumann and Cao 2009). Peroxiredoxin 1 (PRX1) is a ubiquitous 
intracellular antioxidant protein that serves a neuroprotective role through its capacity to 
attenuate ROS levels by undergoing redox cycling via sulfhydryl groups associated with 
its catalytic cysteine residue (Figure 1; Nuemann and Cao 2009). This residue permits 
PRX1 to form intermolecular disulphide-bridged dimers while simultaneously reducing 
hydrogen peroxide or oxygen radicals to water (Cumming et al. 2007). Thioredoxin 
(TRX) and thioredoxin reductase (TRXR) are enzymes that work in concert to reduce the 
disulphide-bridged PRX1 dimers, reactivating the monomers and resetting the redox 
cycle (Cumming et al. 2007). However, the detoxifying capabilities of PRX1 can be 
overwhelmed by excessive ROS generation leading to further oxidation of the cysteine- 
associated thiol (-SH) group to a sulfenic acid (-SOH) species (Cumming et al. 2007). 
Under extreme oxidative stress the sulfenic acid is oxidized to sulfinic acid (-SOOH) and 
 
 
6 
 
ultimately sulfonic acid (-SOOOH; Cumming et al. 2007). These inactive hyperoxidized 
PRX1 monomers are consequently polyubiquitinated by E6-associated protein (E6AP) 
and degraded by the proteasome (Cumming et al. 2007).  PRX1 protein levels decrease 
following mHtt expression in a PC12 nerve cell model, while overexpression of wild-
type, but not a catalytically inactive PRX1 variant, can partially suppress mHTT toxicity; 
suggesting that a compromised antioxidant defense may play a role in potentiating HD 
pathophysiology (Pitts et al. 2012). However, the mechanism by which mHtt expression 
decreases PRX1 levels is currently unknown. The antioxidant response element (ARE) is 
a regulatory enhancer sequence present in the promoters of many antioxidant genes (i.e. 
Prx1 and Trx/TrxR) as well as Phase II detoxifying genes i.e. glutatione-S-transferase 
(Gst) and heme oxygenase (HO); and is positively regulated by nuclear factor erythroid 2-
related factor 2 (NRF2) in response to oxidative stress (He and Ma 2010).  NRF2 is a 
redox-sensitive transcription factor, which is normally sequestered in the cytoplasm by F-
actin-bound Kelch-like ECH-associated protein 1 (KEAP1) resulting in E3 ligase-
mediated polyubiquitination of the complex and subsequent proteosomal degradation 
(Furukawa and Xiong 2005; Taguchi 2010).  Under oxidative stress conditions, critical 
cysteine residues associated with the KEAP1 redox-sensing domain are oxidized, causing 
a conformational change such that KEAP1 is no longer capable of binding NRF2 
(Furukawa and Xiong 2005). This results in the translocation of NRF2  into the nucleus 
via importin α, where it binds the transcriptional co-activator musculoaponeurotic 
fibrosarcoma oncogene homolog (MAF) and initiates transcription of ARE-associated 
genes (Figure 2; Furukawa and Xiong 2005). Additional transcriptional co-factors are 
required for normal expression of ARE-directed gene expression; for example the 
regulatory regions of HO and Gst have multiple Activating Protein 2 (AP-2) and 
Specificity Protein 1 (SP1) binding sites, and are dependent on these factors for high 
levels of expression (Lavrovsky et al. 1994; Moffat 1996). Interestingly, SP1 interacts 
specifically with polyglutamine protein motifs and has been demonstrated to bind the 
mHTT polyglutamine region in vivo, suggesting that mHTT not only causes a destructive 
increase in ROS levels, but may simultaneously compromise an appropriate antioxidant 
transcriptional response (Trushina et al. 2003). In addition to controlling antioxidant 
genes, NRF2 also undergoes AP-2/SP1-dependent autoregulation of its own expression 
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(Chan et al. 1996). Hence, the potential effect of mHTT-SP1 interactions may lead to 
decreased expression of ARE genes, including Nrf2, effectively crippling the cell’s 
antioxidant response. Chemical compounds which form adducts with KEAP1 such that 
the KEAP1/NRF2 complex can no longer assemble mimics oxidative activation of NRF2 
and results in stabilization and translocation of NRF2 into the nucleus (He and Ma 2010). 
Chemical augmentation of NRF2 by KEAP1 inhibition using Carnosic acid or 
triterpenoid derivatives has yielded promising evidence that increasing ARE-directed 
gene expression can attenuate toxicity in HD (Stack et al. 2010; Yang et al. 2009). Since 
excessive oxidative stress is directly related to pro-apoptotic cellular programmes and 
ultimately neurodegeneration in HD, chemicals that inhibit KEAP1 and promote NRF2 
transcriptional activity may boost the antioxidant response and increase the longevity and 
functionality of HD-affected neurons (He and Ma 2005). 
1.5 2,3-Dimercaptopropanol 
2,3-Dimercaptopropanol (DMP) was first synthesized in 1940 under the pseudonym 
British anti-lewisite (BAL) and was implemented as an antidote to the neurotoxic 
chemical weapon Lewisite  (C2H2AsCl3; Pavlic et al. 1949).  Arsenic and other heavy 
metals react with important metabolic enzymes such a pyruvate dehydrogenase (PDH) by 
chemically interacting with adjacent thiol groups forming a chelate that inactivates the 
enzyme, leading to lactic acidosis and apoptosis (Petrick et al. 2001). DMP’s utility in 
counteracting heavy-metal toxicity arises from its adjacent thiol groups, which serve as 
an alternative target for the toxic metal (Vilensky and Redman 2003). As a result of its 
thiol-mediated heavy-metal chelating properties, DMP has been effective in preventing 
systemic arsenic poisoning associated with Lewisite exposure (Vilensky and Redman 
2003). DMP has also been administered to treat high copper levels associated with 
Wilson’s Disease, and is still used today in treating lead, mercury and gold poisoning 
(Vilensky and Redman 2003). Consequently, DMP was evaluated as a HD treatment for 
its heavy metal chelating properties in the early 1950s when HD was also believed to be 
caused by excessive copper accumulation in the brain (Vilensky and Redman 2003). 
Administration of DMP to two HD patients by intramuscular injection over the course of  
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Figure 1. PRX1 detoxifies ROS by undergoing redox cycling. PRX1 is able to reduce 
oxidized functional groups (i.e. ROOH) by reacting with other PRX1 monomers via a 
reactive cysteine residue, which results in the elimination of water and the formation of 
disulphide-bridged PRX1 dimers. Trx reduces these dimers back to their catalytically-
active monomeric state using NADPH reducing equivalents. If intracellular ROS levels 
exceed the tandem reductive capabilities of PRX1 and TRX, the catalytic cysteine residue 
becomes progressively oxidized to a sulfenic, sulfinic and ultimately sulfonic acid; an 
irreversible event leading to the degradation of PRX1 by the proteasome. Image kindly 
provided by Dr. Robert Cumming. 
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Figure 1 
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Figure 2. NRF2 Regulation by Oxidative Stress. In the cytoplasm NRF2 remains in 
complex with KEAP1 resulting in polyubiquitination and degradation of both proteins. If 
sufficient oxidative stress exists in the cell, redox-sensing KEAP1 cysteine residues are 
oxidized resulting in the dissociation of the NRF2/KEAP1 complex, and the subsequent 
translocation of NRF2 into the nucleus. In the nucleus, NRF2 binds the ARE in its target 
gene promoters (i.e. Prx1, HO and Nrf2) and enhances transcriptional activity. 
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Figure 2 
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a year led to a dramatic reduction of HD symptoms, but was discontinued due to practical 
difficulties in administering the drug as well as pain and abscesses at the injection site 
(Nielsen and Butt 1955).  Furthermore, a subsequent study of a broader number of HD 
patients revealed copper levels that were normal, indicating that a copper imbalance does 
not contribution to HD pathogenesis (Campbell et al. 1961).In a blind screen of 1040 
FDA approved compounds, which suppressed mHTT-induced toxicity in a rat PC12 cell 
model, DMP was identified as a strongly neuroprotective agent, but was largely 
disregarded by the authors (Aitken and Schweitzer 2004). DMP has further been 
established as a potent inhibitor of KEAP1, forming S-alkylation adducts with the protein 
such that it dissociates from NRF2, permitting NRF2 nuclear translocation and 
transcriptional activity (He and Ma 2010). Interestingly, treatment of PC12 cells with 
DMP prevents loss of PRX1 protein following expression of mHtt-103Q and increases 
cell viability (Pitts et al. 2012). The precise mechanism by which DMP exerts 
neuroprotection in an HD context remains unknown, but because PRX1 is a downstream 
effector of NRF2 it stands to reason that the neuroprotective properties of DMP may be 
mediated by NRF2 stabilization (Figure 3; Kim et al. 2007).  A more broad understanding 
of DMP’s effect on NRF2 and its effectors will be useful for future HD drug discovery as 
well as the exploration of other potential therapeutic targets to ameliorate the disease. 
1.6 Hypothesis and Investigational Plan 
It is hypothesized that expression of mHtt will interfere with NRF2-dependent ARE-
directed gene expression (i.e. Prx1) thereby exacerbating oxidative stress in the cell. 
DMP counters this effect by triggering NRF2 nuclear translocation and increased ARE-
directed gene expression. This study aims to determine the mechanisms by which DMP, 
and possibly other NRF2-activating compounds, exert a neuroprotective effect on mHTT-
induced toxicity using a PC12 nerve-cell line capable of inducible expression of mHtt.  It 
will be important to determine if loss of PRX1 protein is correlated with mHTT toxicity.  
Additionally, I will determine if ectopic expression of PRX1 correlates with 
neuroprotection against mHTT toxicity. I will also investigate the effect of mHtt 
 
 
13 
 
expression and DMP treatment on NRF2 subcellular localization and PRX1 oxidation 
state, as well as ARE gene transcript levels. To establish whether or not NRF2 activation 
plays a role in DMP-mediated neuroprotection, I will use an NRF2-responsive ARE-
Luciferase reporter construct to quantify levels of NRF2 transcriptional activity following 
either DMP treatment or induced expression of mHtt.  
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Figure 3. Hypothesized mechanism by which DMP confers neuroprotection. DMP is 
believed to form chemical adducts with KEAP1, changing the conformation of the 
protein or blocking its association with NRF2, resulting in NRF2 nuclear translocation 
and transcriptional activity.   
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CHAPTER 2 
Materials and Methods 
2.1 Cell Culture Conditions 
PC12-103Q-GFP cells were obtained from Leslie Thompson (UC Irvine, CA) and 
maintained in DMEM (Biowhittaker) supplemented with 10%  Horse Serum (HS), 5% 
Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin at 37•C in a humidified CO2 
incubator with 5% CO2/95% air. These cells are stably transfected with a plasmid 
encoding exon 1 of the HD gene with a pathogenic 103Q repeat fused in frame to the 
coding sequence of enhanced GFP at the carboxy terminus, under the control of an 
inducible ecdysone promoter. Transcription of the transgene was activated by treating 
cells with 2.5 µM Tebufenozide (an ecdysone analogue) in the culture medium. This cell 
line exhibits rapid (48h) and extensive (>50%) cell death after induction of mHtt-103Q 
expression. 
2.2 PRX1 expression plasmids and transfection 
Expression constructs containing FLAG-tagged versions of both wild type (WT) and 
cysteine mutant (C52S) Prx1 cDNAs cloned into pcDNA 3.1 were generously supplied 
by Dr. Hyunjung Ha (Chungbuk National University, Cheonju Korea). PC12-Htt-103Q-
GFP cells were seeded in 35-mm dishes at 3 x 105 cells/dish and co-transfected with 
either pcDNA or FLAG-tagged PRX1 expression constructs along with a mCherry 
Fluorescent Protein reporter plasmid at a 3:1 molar ratio for a total of 4 μg of DNA per 
dish using Lipofectamine 2000 (Invitrogen) in Opti-MEM media. Plasmid DNA mixed 
with 4 μl of Lipofectamine 2000 in Opti-MEM media was added to PC12 cell cultures, 
and 6 h later the transfection media was replaced with DMEM containing 10% HS and 
5% FBS. The following day, transfected cells were treated with 2.5 μM Tebufenozide to 
induce mHtt expression and at 48 hours post-induction, cells were trypsinized and scored 
for cell viability by trypan blue dye exclusion using a hemocytometer and both light and 
epifluorescent microscopy. Viability in successfully transfected cells was assessed by 
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comparing the average number of mCherry positive (successfully transfected) and trypan 
blue negative (living) cells after Tebufenozide induction, versus cells transfected with the 
same plasmid, but without Tebufenozide treatment. This indicates the extent to which the 
plasmid confers neuroprotection in the presence of mHTT expression. Mean cell viability 
ratios from three independent experiments were analyzed using a one way ANOVA and 
post-hoc Tukey test. 
2.3 MTT Cell Viability Assays 
For MTT cell viability assays PC12 Htt-103Q-GFP cells were seeded in quadruplicate at 
7 x 103 cells/well in 96-well plates (100 μl total culture volume). DMP as well as 
structurally related compounds 3-mercaptopropanol (3MP)  and glycerol, in addition to 
ARE-activators 1,2-Dithiole-3-thione (D3T), Oltipraz, tert-Butylhydroquinone (tBHQ) 
and Carnosic acid (Figure 5A) were added at various concentrations (1, 5, 10, 50 and 100 
μM) to 96-well plates 24 h after seeding cells. One hour after compound exposure, 
transgene expression was induced with 2.5 μM Tebufenocide. 48 hours after induction of 
mHtt-103Q-GFP expression 10 μL of a 5 mg/ml MTT solution prepared in PBS was 
added to the culture media and incubated at 37oC for two hours. Media was thoroughly 
aspirated from the wells and rinsed twice with PBS; the purple formazan product of MTT 
was released from cells by the addition of 100 μL of DMSO. Absorbance was measured 
at a test wavelength of 595 nm and reference wavelength of 655 nm using a BioRad 3550 
microplate reader. Mean cell viability ratios from three independent experiments were 
analyzed using a one way ANOVA and post-hoc Tukey test. 
2.4 RT-PCR 
RNA was extracted from PC12 cells using TRIzol reagent (Invitrogen) following the 
manufacturer’s protocol. Briefly, 1 μg total RNA was reverse transcribed into cDNA 
using a 1st Strand cDNA Synthesis kit (Quanta BioSciences Inc). RT-PCR was 
performed using a mastercycler thermocycler (Eppendorf) for 30 cycles for Prx1 and 27 
cycles for GAPDH as a control. Each cycle included denaturation at 94°C for 20s, 
primer-specific annealing temperatures for 45s and elongation at 72°C for 45 s. The 
primers used for Prx1 were For– 5’CCTGTAGCTCGACTCTGCTGATAG3’ and Rev– 
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5’ GCGGCCAACAGGAAGATC 3’ with an annealing temperature of 57°C (Jiang and 
Stefanovic 2008),  for GAPDH were For- 5’CCTTCATTGACCTCAACTAC3’, and 
Rev–5’GGAAGGCCATGCCAGTGAGC3’ with an annealing temperature of 64°C (Lee 
et al. 2009),  for HO were For- 5’GGGTGACAGAAGAGGCTAAGACC3’ and Rev- 
5’AGATTCTCCCCTGCAGAGAGAAG3’ with an annealing temperature of 60°C 
(Scapagnini et al. 2002) and for Nrf2 were For- 
5’TTCCTCTGCTGCCATTAGTCAGTC3’ and Rev- 
5’GCTCTTCCATTTCCGAGTCACTG3’ with an annealing temperature of 55°C (Ikeda 
et al. 2000). Each primer set was run at 28, 30 and 32 cycles to verify that amplification 
was occurring only within the resolvable linear range. The size of the PCR products was 
determined by 1% agarose gel electrophoresis with visualization by ethidium bromide 
staining. Amplicon band intensity was analyzed by ImageJ software and expressed 
relative to GAPDH band intensity. Mean relative band intensity from three independent 
experiments were analyzed using a one way ANOVA and post-hoc Tukey test. 
2.5 Subcellular Fractionation and SDS PAGE/Immunoblot 
For nuclear/cytoplasmic subcellular fractionation, PC12 Htt-103Q-GFP cells were seeded 
on 10 cm dishes at 1.5 x 106 cells/dish. Cells were treated with 100 µM DMP, 2.5 µM 
Tebufenozide, or 100 µM DMP + 2.5 µM Tebufenozide for 0, 24, 48 and 72 hours 
respectively. Cells were then washed with PBS and centrifuged at 800 x g for 1 minute in 
an Eppendorf 5415R centrifuge and resuspended in 100 µL of hypotonic lysis buffer (20 
mM Tris-HCl; pH 7.4, 10 mM NaCl, 3 mM MgCl2). Cells were then incubated on ice for 
15 minutes and lysed using 10 µL of 10% NP-40 (Sigma), and centrifuged at 6000 x g for 
5 minutes. The cytoplasmic supernatant was transferred to a separate tube and the nuclear 
pellet was washed twice in hypotonic lysis buffer + 1% NP-40 and resuspended in 100 
µL of SDS lysis buffer (50 mM Tris pH 7.5, 2% SDS, 1 mM PMSF and 10 mM 
iodoacetamide). Protein extracts (30 μg) were treated with 100 mM DTT and 2% β-
mercaptopropanol (BME), boiled for 5 min and then resolved by 12% PAGE using a 
BioRad electrophoresis apparatus. Gels were electroblotted onto Immobilon-P membrane 
(Millipore, Bedford, MA), blocked with 1% milk and 3% BSA (Sigma) in Tris-buffered 
saline with 0.5% Tween-20 (TBS-T). Membranes were incubated overnight with 
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polyclonal rabbit antibodies against NRF2 (Santa Cruz Biotechnology), Prx-1 
(AbFrontier), sulfonylated Prx (AbFrontier), GFP (Sigma), Actin (Cell Signaling) or 
Histone H3 (Cell Signalling). Following incubation, membranes were washed with TBS-
T and further hybridized with horse-radish peroxidase-conjugated goat anti-rabbit 
secondary antibodies (BioRad). Detection was performed using Pierce ECL Western 
blotting detection reagents (ThermoScientific) and visualized using a ChemiDoc digital 
imaging system (BioRad). Densitometric analysis was performed using ImageJ software 
and expressed relative to actin. Mean relative band intensity from three independent 
experiments were analyzed using a one way ANOVA and post-hoc Tukey test. 
2.6 Luciferase Assay 
For the ARE-Luciferase assay, PC12 Htt-103Q-GFP cells were seeded in 12-well dishes 
at 1.3 x 105 cells/well and transfected with 2 µg of the ARE-Luciferase reporter plasmid 
(Numazawa et al. 2003) as well as 0.2 µg of pRL-TK Rinella Luciferase control plasmid 
(Promega), using 25 µL of Lipofectamine 2000 (Invitrogen) in Opti-MEM media per 
well.   After 6 hrs, the transfection media was replaced with DMEM containing 10% HS 
and 5% FBS and 18 hours post-transfection cells were treated with 100 µM DMP, 2.5 
µM Tebufenozide, or 100 µM DMP + 2.5 µM Tebufenozide for 0, 24, 48 and 72 hours 
respectively. Luciferase assays were carried out using a Dual-Luciferase® reporter assay 
system (Promega), bioluminescence was measured using the Infinite® M1000 PRO 
microplate reader (Tecan). To control for transfection efficiency ARE-associated Firefly 
Luciferase was expressed relative to control Rinella Luciferase bioluminescence; this 
ratio was further expressed as a fold change from the 0 hour timepoint for each treatment. 
Mean relative Luciferase activity from three independent experiments was analyzed using 
a one way ANOVA and post-hoc Tukey test. 
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Chapter 3 
Results 
3.1 Prx1 Overexpression Increases Cell Viability 
Increased expression of mHtt promotes neurotoxicity and loss of Prx1 expression (Pitts et 
al. 2012); therefore, it was of interest to determine if overexpression of Prx1 could 
protect against mHTT-induced toxicity. In addition, to evaluate whether any observed 
neuroprotective effect is strictly dependent on PRX1 antioxidant activity or an alternative 
mechanism, both wild-type (PRX1-WT) and a catalytically-inactive (PRX1-C52S) 
cysteine mutant PRX1 were overexpressed. PC12-103Q-GFP cells transfected with a 
pcDNA 3.1 control vector and induced to express mHtt with Tebufenozide for 48 hours 
underwent a loss of endogenous PRX1, as well as a 37% decrease in cell viability (Figure 
4). Similarly, PC12-103Q-GFP cells expressing the catalytically inactive C52S PRX1 
mutant exhibited toxicity comparable to that of control transfected cells following 
induction of mHtt expression (Figure 4). In contrast, PC12-103Q-GFP cells 
overexpressing Flag-tagged wild-type PRX1 species demonstrated a statistically 
significant increase in viability following induction of mHtt compared to control 
transfected cells (Figure 4). 
3.2 Effect of Potential ARE Activators on mHTT Toxicity 
DMP exposure prevents loss of PRX1 protein levels and suppresses cell death in mHtt 
expressing PC12 cells (Pitts et al. 2012). Maintenance of PRX1 protein has further been 
correlated with increased viability following mHtt expression in PC12 cells (Figure 4).  
PRX1 expression is controlled, in part, by the transcription factor NRF2 binding to ARE 
elements within its promoter regions (Taguchi 2010).   It was therefore of interest to 
evaluate the relative neuroprotective effects of DMP and its structural variants, as well as 
bona fide ARE-activating compounds in a HD context (Figure 5A). Treatment with DMP 
structural variants glycerol and 3MP did not yield any appreciable increases in cell  
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 Figure 4. Maintenance of wild-type Prx1 expression attenuates mHTT toxicity. 
Western blot analysis demonstrated that 48 hours post-mHtt induction PC12-103Q-GFP 
cells transfected with a pcDNA 3.1 control plasmid or catalytically inactive (PRX1-
C52S) PRX1 undergo a loss of endogenous PRX1, which correlates with a decreased in 
cell viability. Overexpression and maintenance of Flag-tagged wild-type PRX1 (PRX1-
WT) correlates with a statistically significant increase in cell viability (*, P<0.01,n=3). 
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Figure 5. DMP and D3T treatment attenuates mHtt toxicity. MTT viability assays 
conducted on PC12-103Q-GFP cells treated with DMP and the structurally related 
compounds 3MP and glycerol; as well as ARE-activating compounds D3T, Oltipraz, 
tBHQ and Carnosic acid (A). Chemical structures were obtained from the PubChem 
project (ID#s 3080, 88211, 753, 68296, 47318, 16043 and 65126, respectively). Drug 
treated cells were induced to express mHtt with Tebufenozide and survival was measured 
at 48 hours post-induction (B; *, P<0.05; **, P<0.01, n=3).   
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Figure 5 (A)     
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viability. Treatment with the ARE-activating compounds Oltipraz, tBHQ and Carnosic 
acid treatment resulted in modest, but not statistically significant increases in cell 
viability following expression of mHtt (Figure 5B).  However, treatment with the 
compound D3T (also an ARE-activator) resulted in statistically significant increases in 
cell viability following expression of mHtt (Figure 5B). Interestingly, DMP treatment 
resulted in the highest level of protection against mHTT toxicity (Figure 5B).  
3.3 ARE-Directed Gene Expression is Affected by DMP and mHTT 
Loss of PRX1 expression correlates with mHTT-induced neurotoxicity (Figure 4), but 
whether this occurs at the transcriptional or post-translational level following mHtt 
expression is unknown. Since Prx1 is regulated by NRF2 via the ARE, three ARE-
regulated transcripts (Prx1, HO and Nrf2) were chosen for examination by semi-
quantitative RT-PCR at 0, 24, 48 and 72 hour time points under control, Tebufenozide, 
DMP and DMP + Tebufenozide treatments. In the untreated control Prx1 and HO 
transcript levels remain constant, while Nrf2 transcript levels oscillate (Figure 6A, C-E). 
Following expression of mHtt using Tebufenozide , there is a statistically significant 
reduction in HO and Nrf2 transcript levels at 24, 48 and 72 hour time points (Figure 6C, 
E) as well as a significant loss of Prx1 transcript at 24 and 48 hours post-treatment 
(Figure 6D). It was also important to ascertain whether the protective effect associated 
with DMP treatment was mediated by ARE transcriptional activation or if PRX1 protein 
maintenance was rather the result of a post-translational mechanism. Indeed, DMP 
treatment resulted in statistically significant increases in HO and Nrf2 transcript levels at 
24 and 48 hours (Figure 6C, E) as well as a significant increase in Prx1 transcript levels 
at 72 hours (Figure 6D). DMP + Tebufenozide treatment resulted in statistically 
significant increases in HO transcripts at 24 and 72 hours post-treatment (Figure 6C), as 
well as maintenance of Prx1 and Nrf2 transcript levels (Figure 6D, E) throughout the 
course of the experiment.   
3.4 Western Blot Analysis of Prx1 and Nrf2 
To determine if the transcriptional changes associated with mHtt expression and DMP 
treatment also resulted in changes in protein expression, Western blot analysis was  
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Figure 6.  Semi-quantitative RT-PCR Analysis of ARE-Directed Gene Expression. 
PC12-103Q-GFP cells were treated with Tebufenozide (A), DMP (B) or Tebufenozide + 
DMP (B) for 0, 24, 48 and 72 hours. Transcripts were detected using HO, Prx1, Nrf2 and 
GAPDH specific primers. Densiometric analysis of band intensity is shown for HO (C), 
Prx1 (D) and Nrf2 (E) relative to GAPDH. Statistically significant changes in gene 
expression in treated relative to untreated cells are indicated (*, P<0.05; **, P<0.01, n=3). 
Each time point was compared relative to the 0H control and no between-treatment 
comparisons were made. The use and adaptation of figures 6(A) and 6(B) has been done 
with permission by the copyright holder © 2012 by The American Society for 
Biochemistry and Molecular Biology, Inc.  
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Figure 6 (C) 
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performed on protein extracts using PRX1- and NRF2-specific antibodies. Protein 
expression profiles were analyzed in untreated (Figure 7A), Tebufenozide (Figure 7B), 
DMP (Figure 7C) and DMP + Tebufenozide (Figure 7D) treated PC12-103Q-GFP cells.  
Since mHTT is fused to GFP in PC12-103Q-GFP cells, a GFP antibody was used to 
measure mHTT levels; extremely low levels of GFP were detected in control and DMP 
treated samples, while dramatically higher levels were found in  Tebufenozide and DMP 
+ Tebufenozide treated cells (Figures 7A-D). Cell extracts were also fractionated into 
cytosolic and nuclear fractions in order to compare the relative nuclear localization of 
NRF2 as cytoplasmic NRF2 is rapidly degraded.  NRF2 levels in the cytoplasm and 
nucleus remained relatively uniform in untreated cells, however with Tebufenozide 
treatment cytoplasmic NRF2 levels underwent a statistically significant increase after 48 
hours, whereas nuclear NRF2 levels were modestly decreased at 6, 24 and 48 hour time 
points (Figure 8). DMP treatment resulted in statistically significant increases in 
cytoplasmic NRF2 levels at 6 and 24 hours, as well as significant increases in nuclear 
NRF2 at 6 and 48 hour time points. The combination of DMP and Tebufenozide 
treatments resulted in a statistically significant increase in cytoplasmic NRF2 levels at 48 
hours post-treatment as well as a significant increase in nuclear NRF2 at the 24 hour time 
point (Figure 8). 
PRX1 protein levels did not exhibit significant variation in untreated control samples and 
underwent a statistically significant decline in Tebufenozide-treated cells at the 48 hour 
time point (Figure 9A). DMP treatment resulted in significant increases in PRX1 protein 
levels at the 24 and 48 hour time points, while the combination of DMP + Tebufenozide 
treatments resulted in a statistically significant increase in PRX1 protein at 48 hours post-
treatment (Figure 9A). In addition, the oxidation state of PRX1 was also measured using 
an antibody that recognizes both irreversibly oxidized species of the protein (PRX1-SO2-
3; Figure 9B). The oxidatively-inactivated PRX1-SO2-3 species underwent a statistically 
significant increase in untreated control samples, while DMP, Tebufenozide and DMP + 
Tebufenozide treatments did not result in any significant changes (Figure 9B). However, 
because the PRX1 antibody does not differentiate between catalytically active PRX1-SH 
and catalytically inactive PRX1-SO2-3, it was necessary to calculate the ratio of oxidized 
PRX1-SO2-3:total PRX1 detected in Figure 9A in order to evaluate the proportion of 
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PRX1 protein that was functionally active (Figure 9C). The ratio of PRX1-SO2-3: total 
PRX1 increased to a statistically significant level by the 48 hour time point in untreated 
control samples, which is likely a reflection of the increased density of cells following 2 
days of culture.  However, following induction of mHtt with Tebufenozide treatment, this 
ratio increased significantly by 6 hours and remained so through the 24 and 48 hour time 
points (Figure 9C). In contrast, DMP treatment resulted in statistically significant 
decreases in the ratio of PRX1-SO2-3: total PRX1 at 6, 24 and 48 hour time points, while 
the combination of DMP + Tebufenozide treatments resulted in modest decreases in this 
ratio, reaching significance by the 48 hour time point (Figure 9C).  
3.5 ARE-Luciferase Activity is Affected by DMP exposure and mHTT 
expression 
In order to definitively establish whether the neuroprotective effect of DMP treatment is 
mediated by activation of NRF2 or some alternative mechanism, an ARE-specific 
luciferase reporter contstruct was transfected into PC12-103Q-GFP cells along with a 
control Rinella luciferase construct. Relative ARE-luciferase activity was determined by 
calculating the ratio of ARE-luciferase bioluminescence:Rinella luciferase 
bioluminescence to control for variable transfection efficiency. Relative ARE-luciferase 
activity in untreated control cells remained uniform and unchanged while Tebufenozide- 
treated cells underwent statistically significant increases at 24, 48 and 72 hour time 
points, peaking at 2.7 fold increased activity (Figure 10). DMP treatment resulted in 
dramatic and statistically significant increases in relative ARE-luciferase activity at 24, 
48 and 72 hour time points, peaking at 12.9 fold increased activity (Figure 10). DMP + 
Tebufenozide treatment also resulted in statistically significant gains in relative ARE-
luciferase activity at 24, 48 and 72 hour time points, peaking at 11.2 fold increased 
activity.   As a positive control, cells were treated with 200 µM H2O2 for two hours 
leading to a 14.9 fold increase in relative ARE-luciferase activity (Figure 10).  
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Figure 7. Western Blot Analysis. PC12-103Q-GFP cells were untreated (A) or exposed 
to Tebufenozide (B), DMP (C) or DMP + Tebufenozide (D) for  0, 6, 24 and 48 hours. At 
each time point, cells were harvested and fractionated into cytosolic and nuclear extracts.  
NRF2 subcellular localization was evaluated to measure NRF2 activity. PRX1 and 
PRX1-SO2-3, levels were analyzed to understand how PRX1 protein levels and oxidation 
state change in response to the treatments above. mHtt expression was assessed using an 
anti-GFP antibody, while histone H3 was used as a nuclear loading control and actin was 
used as a cytoplasmic loading control. The Prx-SO2-3 blot reveals two bands, the upper 
band is Prx2-SO2-3 and the lower band is Prx1-SO2-3. 
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Figure 7 (C) 
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Figure 8. Analysis of NRF2 Protein Levels and Subcellular Localization. Densiometric 
analysis of immunoblots of fractionated cytoplasmic and nuclear extracts revealed that 
NRF2 protein levels significantly increased in the cytoplasm with Tebufenozide 
treatment and both in the cytoplasmic and nuclear compartments with DMP treatment. 
The combination of DMP and Tebufenozide administration also results in statistically 
significant increases in the cytoplasmic and nuclear localization of NRF2 relative to 
untreated cells. Each time point was compared relative to the 0H control and no between-
treatment comparisons were made (*, P<0.05; **, P<0.01, n=3).    
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Figure 8 
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Figure 9. Analysis of PRX1 Protein Levels and Oxidation State. Densiometric analysis 
of PRX1 protein levels demonstrated a statistically significant decrease in PRX1 protein 
levels 48 hours following Tebufenozide treatment, and statistically significant increases 
in PRX1 protein at 24 and 48 hours following DMP treatment compared to untreated 
cells (A). The combination of DMP and Tebufenozide resulted in a significant increase in 
PRX1 protein at 48 hours post-treatment (Figure 9A). Untreated control cells underwent a 
statistically significant increase in oxidized PRX1-SO2-3 at the 48 hour time point, while 
DMP, Tebufenozide and DMP + Tebufenozide treatments did not result in statistically 
significant changes in PRX1-SO2-3 levels (B). Since the PRX1 antibody does not 
discriminate between catalytically active PRX1-SH and catalytically inactive PRX1-SO2-
3, levels of oxidized PRX1-SO2-3 were expressed as a ratio of total PRX1 in order to gauge 
the relative proportion of inactive:active PRX1 protein (C). Each time point was 
compared relative to the 0H control and no between-treatment comparisons were made ( 
*, P<0.05; **, P<0.01, n=3).  
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Figure 10. ARE-Luciferase reporter assay. PC12-103Q-GFP cells were transfected with 
the ARE-luciferase reporter plasmid and a Rinella luciferase control plasmid at a 10:1 
molar ratio and relative ARE-luciferase bioluminescence was quantified by comparing 
the ratio of ARE:Rinella luciferase activity. Tebufenozide, DMP and DMP + 
Tebufenozide treated cells each underwent statistically significant increases in relative 
ARE-luciferase activity at 24, 48 and 72 hours post-treatment. Positive control cells were 
treated with 200 µM H2O2 for two hours. Each time point was compared relative to the 
0H control and no between-treatment comparisons were made (*, P<0.05; **, P<0.01, 
n=3). 
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Chapter 4 
Discussion and Future Research 
4.1 Overview 
In this study I sought to determine the extent to which DMP attenuates mHTT toxicity 
and the mechanism by which DMP exerts a neuroprotective effect in PC12-103Q-GFP 
cells. My results demonstrate that DMP treatment results in 2.5 fold increased viability in 
cells expressing mHTT-103Q. Additionally, I found that the observed neuroprotective 
effect associated with DMP was mediated, at least in part, by increased NRF2 
transcriptional activity resulting in augmented expression of ARE genes such as Prx1 and 
HO, facilitating a more robust antioxidant defense. DMP promoted a high degree of 
NRF2 nuclear translocation and transcriptional activity, and as such may serve as a useful 
therapeutic tool in the treatment of HD and possibly other neurodegenerative diseases. 
4.2 Maintenance of Wild-Type PRX1 Following mHtt Induction Confers 
Neuroprotection 
PRX1 is an important cytoplasmic antioxidant protein responsible for catalyzing the 
reduction of hydrogen peroxide and alkyl hydroperoxides (Rabilloud et al. 2002).  
Oxidative stress associated with mitochondrial perturbation is strongly linked to mHtt 
expression and is a key contributor to the death of striatal neurons in HD patients 
(Landles and Bates 2004). ROS mediated damage to cellular macromolecules, coupled 
with transcriptional repression and oxidative inactivation of crucial antioxidants such as 
PRX1 may contribute to a compromised antioxidant defence in mHtt expressing neurons 
(Krapfenbauer et al. 2003). Cha and colleagues (2009) found that increased expression of 
PRX1 conferred protection against ROS-induced apoptosis in human breast cancer cells 
and Schreibelt et al. (2008) identified a similar effect in brain endothelial cells.  Due to its 
importance in mitigating the effects of oxidative stress resulting from mHtt expression, I 
sought to determine if overexpression of wild-type PRX1 or a catalytic mutant PRX1 
lacking reductase activity was capable of suppressing mHTT toxicity. Indeed, 
maintenance of wild-type PRX1 protein levels, when compared to control transfected 
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cells, correlated with a statistically significant increase in cell viability following 
expression of mHtt. In addition, the absence of even a modest neuroprotective effect 
associated with overexpression of the catalytic mutant PRX1, as compared with the 
transfection control, suggests that neuroprotection attributed to wild-type PRX1 is chiefly 
dependent on redox cycling of its catalytic cysteine residue. 
4.3 DMP Treatment Significantly Reduces mHTT Sensitivity 
NRF2 is a master transcriptional regulator of antioxidant enzymes (i.e. PRX1), phase II 
detoxifying enzymes (i.e. HO) and other neuroprotective proteins (i.e. multi-drug 
resistance transporters) and is tightly regulated by oxidative and electrophilic stress (He 
and Ma 2010). In unstressed conditions NRF2 remains bound to KEAP1 in the cytoplasm 
and is rapidly degraded (with a half-life of ~20 minutes; He and Ma 2010). However, 
DMP is believed to form adducts with KEAP1 such that NRF2 is released from the 
complex and translocated to the nucleus (He and Ma 2010). Interestingly, when various 
NRF2 activators were tested for their ability to counter mHTT toxicity, only D3T and 
DMP exhibited significant protective effects. Both these compounds are sulfur-rich, 
containing two thiol groups in close relative proximity to one another; situated on 
adjacent carbons in DMP while being separated by one carbon in D3T. Oltipraz is 
reportedly an NRF2 activator, but did not result in significant increases in viability 
following mHtt expression, even though it does possess structural similarity to D3T. The 
most obvious distinction between the two compounds is the six-membered pyrazinyl ring 
structure conjugated to the sulfur-containing  group of Oltipraz, suggesting that steric 
inhibition may play a role in limiting access to Oltipraz thiol groups while less bulky 
chemicals such as DMP and D3T more readily form thiol adducts with KEAP1, resulting 
in more robust activation of NRF2. The DMP structural variant 3MP, which has only one 
thiol constituent and a hydroxyl group replacing the second, failed to suppress mHTT 
toxicity, suggesting that two thiol groups are necessary to confer neuroprotection. 
Additionally, the mitochondrial ROS-specific florescent dye Mito Tracker Red was used 
to confirm that DMP its self was not conferring neuroprotection by acting as a direct 
antioxidant (Pitts et al. 2012). 
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4.4 DMP Increases ARE-Directed Gene Expression 
That control PC12-103Q-GFP cells exhibit constant levels of ARE transcripts HO and 
Prx1 while Nrf2 mRNA oscillated, likely results from the fact that NRF2 has a short half-
life and is highly responsive to even transient increases in oxidative stress, which can 
occur with increases in cell density during culture (Li et al. 2004). Interestingly, although 
induction of mHtt with Tebufenozide causes an increase in cellular oxidative stress, by 48 
hours post-treatment, the levels of all three transcripts were significantly diminished. 
These data suggest that the transcriptional effects of mHtt expression override or 
counteract NRF2 activation. mHTT can interact with transcriptional co-factors such as 
AP-1 and SP2 that are required for normal ARE-directed gene expression (Ravache et al. 
2010).  It is likely that increased apoptosis in neurons expressing mHtt is, at least 
partially, a result of increased oxidative stress and transcriptional repression of ARE 
genes (Landles and Bates 2004). Although DMP has never previously been demonstrated 
to increase NRF2 activity in cell culture, its high affinity in vitro interaction with purified 
KEAP1 suggests that this may be the case (He and Ma 2010). Indeed, by 48 hours 
following DMP treatment HO and Nrf2 (which activates its own expression) mRNA 
levels were both increased and by 72 hours, levels of all three transcripts significantly 
increased, providing support that DMP suppresses mHTT toxicity via an NRF2/ARE 
mechanism (Pitts et al. 2012). DMP treatment also prevented a loss of ARE transcripts 
associated with mHtt expression, resulting in maintenance of Prx1 and Nrf2 mRNA and 
significantly increased HO expression. These data provide compelling evidence that 
DMP may serve a therapeutic role in sustaining ARE-directed gene expression even 
when combined with mHTT-related transcriptional insults. 
4.5 DMP Increases Nuclear NRF2 Protein Levels 
In this study, induction of mHtt resulted in significant accumulation of cytoplasmic, but 
not nuclear NRF2, suggesting that mHTT prevents NRF2 localizing to the nucleus even 
under oxidative stress. Accordingly, mHTT is known to interact with microtubule motors, 
causing intracellular trafficking defects. Hence, the apparent disruption of NRF2 nuclear 
translocation may partly explain transcriptional repression of ARE genes associated with 
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mHtt expression (Li et al. 1998). Furthermore NRF2 trafficking deficits have been well 
documented in HD-related neurodegenerative disorders such as Friedrich’s ataxia; a 
trinucleotide repeat expansion disorder characterized by elevated neurotoxicity also 
resulting from an inadequate antioxidant response to oxidative stress (Paupe et al. 2009). 
DMP, in contrast, significantly increases cytoplasmic and nuclear NRF2 levels together; 
which is potentiated by NRF2’s positive regulation of its own expression, forming a 
positive feedback loop that maintains high NRF2 protein levels (He and Ma 2010). 
KEAP1 is responsible for binding NRF2 and acting as an adapter for E3 ubiquitin ligase 
to target the complex for degradation (He and Ma 2010). There is also evidence that 
KEAP1 is able to translocate into the nucleus and remove transcriptionally active NRF2 
from its ARE promoter sequences (Furukawa and Xiong 2005). Therefore, it is possible 
that inhibition of KEAP1 by DMP prevents both the degradation of NRF2 in the 
cytoplasm and its transcriptional inactivation in the nucleus. DMP treatment in 
combination with induction of mHtt also resulted in a significant increase in both 
cytoplasmic and nuclear NRF2 protein levels, indicating that the effects of DMP are 
adequately robust even in the presence of high levels of mHTT.   
4.6 DMP Increases PRX1 Expression and Reduces PRX1-SO2-3 Protein Levels 
PRX1 is an important antioxidant protein related to cell survival, its expression levels are 
elevated in numerous human cancers including mesothelioma, adenocarcinoma and 
squamous carcinoma and elevated PRX1 has been implicated in chemotherapy resistance 
(Kim et al. 2007). Induction of mHtt with Tebufenozide causes diminishment of PRX1 
protein levels resulting from ARE transcriptional repression, in addition to increased 
post-translational inactivation and degradation as indicated by significant increases in the 
proportion of PRX1 in the cytoplasm that has been inactivated by irreversible oxidation. 
DMP indirectly increases PRX1 expression by KEAP1 inhibition and the concomitant 
activation of NRF2, while significantly reducing the relative abundance of inactivated 
PRX1-SO2-3, thereby enhancing the cell’s antioxidant defense (He and Ma 2010). 
Maintenance of PRX1 in a reduced (active) state is partly controlled by the enzyme 
thioredoxin 1 (Trx1); an enzyme also regulated by NRF2 (Tanito et al. 2007).  It is 
therefore possible that DMP simultaneously activates increased expression of both PRX1 
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and Trx1 to ensure and optimal antioxidant response (Tanito et al. 2007). Future studies 
will evaluate this hypothesis. 
4.7 DMP Increases NRF2/ARE-Luciferase Activity 
Inferences regarding DMP-mediated NRF2 activation were initially made based on 
indirect evidence such as nuclear NRF2 localization and increased ARE-controlled 
mRNA and protein levels, so it was necessary to use an ARE-luciferase reporter assay to 
definitively establish the effects of DMP and mHTT on NRF2 activity. Control cells 
demonstrated uniform ARE-luciferase activity coinciding with constant levels of nuclear 
NRF2 protein as well as HO and Prx1 transcript levels. Induction of mHtt expression 
resulted in significant increases in ARE-luciferase activity presumably caused by 
increased oxidative stress associated with mitochondrial dysfunction.  Curiously, despite 
these increases in ARE-luciferase activity, the nuclear NRF2 levels remained relatively 
unaffected by mHtt expression while the ARE-directed transcripts HO and Prx1 in fact 
undergo significant diminution. Since expression of ARE-luciferase is not attenuated in a 
similar manner to that of HO and Prx1 mRNA, these data suggest that specific 
interactions between mHTT and other transcriptional cofactors such as SP1 or AP2 may 
have a more potent effect on HO and Prx1 expression than global transcriptional 
repression associated with HD (Ravache et al. 2010).  In contrast, DMP treatment 
increased ARE-luciferase activity to a much more dramatic extent, maintaining a >10 
fold rise in activity throughout the course of the experiment, demonstrating a robust and 
NRF2-specific mechanism by which DMP exerts neuroprotection. DMP treatment alone 
or coupled with mHtt expression caused significantly increased ARE-luciferase activity 
comparable to the H2O2 positive control, indicative of profoundly increased ARE 
transcriptional activity, presumably mediated by NRF2. Although DMP potentiated 
activation of ARE elements, this finding does not preclude the possibility of DMP 
activating other ARE-associated transcription factors. To date, no other transcription 
factors that directly bind and activate the ARE have been identified, strongly suggesting 
that DMP is exerting its effect via NRF2.   
4.8 Conclusions and Future Directions 
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The neuroprotective properties of DMP in a HD context have previously been reported by 
Aitken et al. (2004) and have since been confirmed in this study. HD neurotoxicity is 
caused in part by oxidative stress combined with a compromised antioxidant defense. 
Accordingly, I have identified significant reductions in ARE-directed transcript levels as 
well as relative reductions in PRX1 protein levels (Landles and Bates 2004). Functional 
maintenance of wild-type PRX1 protein contributes to the neuroprotective role of DMP, 
as ectopic expression of PRX1 increases cell viability and DMP promotes increased 
PRX1 transcription and protein levels while preventing catalytic inactivation of the 
enzyme by oxidation. The mechanism by which DMP increases Prx1 mRNA and protein 
levels was identified as NRF2 activation, confirmed by augmented ARE-directed gene 
expression, increased nuclear localization of NRF2 and dramatically enhanced ARE-
luciferase reporter activity. To further support these findings, a constitutively active form 
of NRF2 NRF2 could be overexpressed in PC12-Htt-103Q-GFP cells to determine if this 
protein alone confers protection against mHTT toxicity. Conversely, experimental 
knockdown of Prx1 followed by DMP treatment would help to establish the extent to 
which DMP’s neuroprotection is dependent on PRX1. Likewise NRF2 knockdown 
should be carried out with DMP treatment to determine if DMP exerts a protective effect 
in the absence of NRF2. Persistence of neuroprotection with knockdown of NRF2 may 
indicate that DMP itself acts as either an antioxidant or affects other protective pathways.  
Regardless of the exact mechanism, the ability of DMP to suppress mHTT toxicity and 
maintain a robust antioxidant response, indicates that this compound is worthy of future 
investigation as a potential therapy for prolonging the lifespan of HD-affected neurons 
and delaying onset of HD in presymptomatic patients.  
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